Understanding Barriers Along the Patient Journey in Alzheimer’s Disease Using Social Media Data by Amir Abbas Tahami Monfared, Yaakov Stern, Stephen Doogan, Michael Irizarry, Quanwu Zhang

Get full text

Plasma pTau181 enhances the prediction of future clinical decline in amyloid‐positive mild cognitive impairment by Viswanath Devanarayan, Daniel A. Llano, Yan Helen Hu, Harald Hampel, Lynn Kramer, Shobha Dhadda, Michael Irizarry

Get full text

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease by Shobha Dhadda, Michio Kanekiyo, David Li, Chad J. Swanson, Michael Irizarry, Scott Berry, Lynn D. Kramer, Donald A. Berry

Get full text

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease by Lawrence S. Honig, Jerome Barakos, Shobha Dhadda, Michio Kanekiyo, Larisa Reyderman, Michael Irizarry, Lynn D. Kramer, Chad J. Swanson, Marwan Sabbagh

Get full text

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 pro... by Eric McDade, Jeffrey L. Cummings, Shobha Dhadda, Chad J. Swanson, Larisa Reyderman, Michio Kanekiyo, Akihiko Koyama, Michael Irizarry, Lynn D. Kramer, Randall J. Bateman

Get full text

Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease by Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer

Get full text

Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease by Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer

Get full text